Core Viewpoint - Fosen Pharmaceutical has received approval from the National Medical Products Administration of China for its product, Nicardipine Hydrochloride Injection, which is intended for the emergency management of abnormal hypertension during surgery and hypertensive emergencies [1][2] Group 1: Product Approval and Market Potential - The consistency evaluation application for Nicardipine Hydrochloride Injection has been approved, indicating its readiness for clinical use [1] - The sales scale of Nicardipine Hydrochloride Injection in Chinese public medical institutions is projected to exceed 600 million RMB in 2024, with a double-digit growth rate expected from 2022 to 2024, showing year-on-year increases of 35.71%, 16.09%, and 14.14% respectively [1] - The product is recognized as a first-line treatment in various hypertension management guidelines, including the 2020 International Society of Hypertension's Global Hypertension Practice Guidelines and the Chinese Hypertension Emergency Diagnosis and Treatment Guidelines [1] Group 2: Product Advantages and Specifications - Nicardipine Hydrochloride Injection is noted for its rapid onset, stable blood pressure reduction, and comprehensive organ protection, with a non-toxic metabolic profile and enhanced vascular selectivity [2] - The company has been selling the 5ml:5mg specification in the domestic market for several years, achieving high market recognition, and has also received approval for additional specifications of 2ml:2mg and 10ml:10mg [2] - Fosen Pharmaceutical is one of the few companies in China to offer a complete range of specifications for Nicardipine Hydrochloride Injection, catering to diverse patient treatment needs [2]
福森药业(01652.HK)：”盐酸尼卡地平注射液“一致性评价申请获批上市